| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-06-06 | GALE-301 GALE-302 (Folate Binding Protein (FBP)) | ovarian cancer, endometrial cancer | 1-2a | Galena Biopharma (USA - OR) | Cancer - Oncology |
| 2016-06-06 | rucaparib | pancreatic cancer | 2 | Clovis Oncology (USA - CO) | Cancer - Oncology |
| 2016-06-06 | NiCord® (expanded cell graft derived from an entire unit of umbilical cord blood enriched with stem cells) | hematological malignancies | 1-2 | Gamida Cell (Israel) | Cancer - Oncology |
| 2016-06-06 | VXM01 | pancreatic cancer | 1-2 | Vaximm (Switzerland - Germany) | Cancer - Oncology |
| 2016-06-06 | rucaparib | ovarian cancer, fallopian tube cancer, primary peritoneal cancer | 2 | Clovis Oncology (USA - CO) | Cancer - Oncology |
| 2016-06-06 | ANAVEX2-73 (tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride) | fragile X syndrome | preclinical | Anavex Life Sciences (USA - NY) | Rare diseases - Genetic diseases |
| 2016-06-06 | VXM01 | pancreatic cancer | 1 | Vaximm (Germany) | Cancer - Oncology |
| 2016-06-06 | IMCgp100 | melanoma | 1 | Immunocore (UK) | Cancer - Oncology |
| 2016-06-06 | binimetinib (MEK162) | advanced NRAS mutant melanoma | 3 | Array BioPharma (USA - CO) | Cancer - Oncology - Rare diseases |
| 2016-06-06 | galinpepimut-S (human Wilms tumor protein 1 peptides - WT1 vaccine) | malignant pleural mesothelioma | 2 | SELLAS Life Sciences (Switzerland) | Cancer - Oncology - Rare diseases |
| 2016-06-06 | POL6014 | cystic fibrosis, alpha-1 antitrypsin (AAT) deficiency | 1 | Polyphor (Switzerland) | Infectious diseases - Rare diseases - Respiratory diseases |
| 2016-06-05 | IMAB362 in combination with epirubicin, oxaliplatin, and capecitabine | CLDN18.2-positive, advanced, unresectable, recurrent or metastatic gastroesophageal cancer | 2 | Ganymed Pharmaceuticals (Germany) | Cancer - Oncology |
| 2016-06-05 | Cabometyx™ (cabozantinib ) | advanced renal cell carcinoma | 3 | Exelixis (USA - CA) Ipsen (France) | Cancer - Oncology |
| 2016-06-05 | cobimetinib and atezolizumab | metastatic colorectal cancer | 1b | Genentech, a member of Roche Group (USA - CA - Switzerland) Exelixis (USA - CA) | Cancer - Oncology |
| 2016-06-04 | CRS-207 | unresectable malignant pleural mesothelioma | 1b | Aduro Biotech (USA - CA) | Cancer - Oncology - Rare diseases |
| 2016-06-04 | encorafenib and cetuximab | patients with advanced BRAF-mutant colorectal cancer | 2 | Array BioPharma (USA - CO) | Cancer - Oncology |
| 2016-06-04 | Opdivo® (nivolumab)+Yervoy® (ipilimumab) | non-small cell lung cancer | 1b | BMS (USA - NY) | Cancer - Oncology |
| 2016-06-04 | CDX-1401 and CDX-301 | malignant melanoma | 2 | Celldex Therapeutics (USA - NJ) National Cancer Institute (USA) | Cancer - Oncology |
| 2016-06-04 | OBI-822/OBI-821 (formerly OPT?822/OPT-821) | metastatic breast cancer | 2-3 | OBI Pharmaceuticals (Taiwan) | Cancer - Oncology |
| 2016-06-04 | PEGPH20 | pancreatic cancer | 2 | Halozyme Therapeutics (USA - CA) | Cancer - Oncology |
